Novel association between serum pentraxin‐2 levels and advanced fibrosis in well‐characterised patients with non‐alcoholic fatty liver disease
Alimentary Pharmacology & Therapeutics2015Vol. 42(5), pp. 582–590
Citations Over TimeTop 15% of 2015 papers
Elizabeth C. Verna, Janki Patel, Richele Bettencourt, P. Nguyen, Carolyn Hernandez, Mark A. Valasek, Tatiana Kisselva, David A. Brenner, Rohit Loomba
Abstract
PTX-2 levels are significantly lower in patients with NAFLD compared to non-NAFLD controls, and decline further in patients with advanced fibrosis. PTX-2 may therefore be both a biomarker of disease and a potential target for anti-fibrotic therapy with the recombinant pentraxin-2.
Related Papers
- → Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018(2020)59 cited
- → TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease(2012)33 cited
- → Effect of probe size and energy (M versus XL probe) on the detection of liver stiffness using transient elastography (Fibroscan)(2011)
- → Transient Elastography: From Research to Noninvasive Assessment of Liver Fibrosis Using Fibroscan®(2018)
- → Impact of probe choice on diagnostic performance of vibration controlled transient elastography(2020)